This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Transcept Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript

Stocks in this article: TSPT

Transcept Pharmaceuticals (TSPT)

Q2 2012 Earnings Call

August 13, 2012 4:30 pm ET

Executives

Thomas P. Soloway - Chief Operating Officer and Executive Vice President

Glenn A. Oclassen - Chief Executive Officer, President and Director

Leone D. Patterson - Chief Financial Officer and Vice President

Analysts

Charles C. Duncan - JMP Securities LLC, Research Division

William Tanner - Lazard Capital Markets LLC, Research Division

Jason M. Gerberry - Leerink Swann LLC, Research Division

Ed Arce - McNicoll, Lewis & Vlak LLC, Research Division

Presentation

Operator

Good day, ladies and gentlemen, and welcome to Transcept Pharmaceuticals Second Quarter 2012 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call may be recorded. I would now like to hand the conference over to Mr. Tom Soloway, Executive Vice President and Chief Operating Officer. Sir, you may begin.

Thomas P. Soloway

Thank you, operator, and good afternoon, everyone. Thank you for joining us today to discuss the Transcept Pharmaceuticals' 2012 second quarter results. My name is Tom Soloway, Executive Vice President and Chief Operating Officer of Transcept. And joining me on the call today are Glenn Oclassen, President and Chief Executive Officer; and Leone Patterson, our newly appointed Vice President and Chief Financial Officer.

After market close this afternoon, we released financial results for the quarter ended June 30, 2012. A copy of this press release is available on our website and has been filed on Form 8-K with the SEC. In addition, we plan to file our Form 10-Q with the SEC this afternoon and encourage everyone to read these documents. We remind you that this conference call will contain forward-looking statements that are intended to be covered under the Safe Harbor provided by the Private Securities Litigation Reform Act. Examples of such statements include, but are not limited to: plans by Purdue Pharma to invest approximately $100 million in the commercialization of Intermezzo, including the timing and nature of the investment; the formation, size and utilization of an Intermezzo sales force and plans to conduct direct-to-consumer advertising, including the timing and feasibility of such plans; the capabilities of the Purdue managed care organization, including providing patient co-pay coupons and our expectations regarding Purdue's ability to successfully commercialize Intermezzo, including via physician and patient education; our expectations regarding future marketing efforts and effectiveness thereof; our expectations regarding the benefits of Purdue's marketing and other efforts on the commercialization of Intermezzo; our beliefs regarding the timing, size and nature of commercial opportunities for Intermezzo, including managed care placement, as well as physician and patient acceptance; our beliefs regarding the challenges facing the commercialization of Intermezzo and Purdue's ability to address such challenges; our expectation of Orange Book listing and receipt of the $10 million milestone payment from Purdue; our expectations regarding the trajectory of prescriptions for and revenue derived from Intermezzo and the timing of such projections; our beliefs regarding intellectual property and product exclusivity for Intermezzo and its importance and duration; our beliefs regarding the accounting treatment and adjustment of royalties on net sales of Intermezzo generated by Purdue; our beliefs regarding the importance of Intermezzo prescription growth as an indicator of success; our beliefs regarding the potential benefits of TO-2061 and our plans to develop TO-2061, our investigational product for the treatment of obsessive compulsive disorder, and expectations for enrollment, completion, top line data availability and the timing of our end of Phase II meeting it with the FDA. These statements are based on information that is available to us today. We may not actually achieve our goals, carry out our plans or intentions, or meet the expectations or projections disclosed in our forward-looking statements. And you should not place undue reliance on these statements.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs